Epidermal growth factor receptor exon 20 insertion variants in non-small cell lung cancer patients.
EGFR
Exon 20 insertions
NGS
NSCLC
Target therapy
Journal
Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
10
05
2021
revised:
18
10
2021
accepted:
15
11
2021
pubmed:
22
11
2021
medline:
18
1
2022
entrez:
21
11
2021
Statut:
ppublish
Résumé
Epidermal growth factor receptor (EGFR) exon 20 insertions occur rarely among different cancer types, with the highest frequency reported among non-small-cell lung cancer (NSCLC) patients, particularly adenocarcinomas (ADCs). Exon 20 insertions fall back in the tyrosine kinase domain, and can be clustered into two principal groups represented by in frame insertions and three to 21 bp (corresponding to 1-7 amino acids) duplications within amino acids 762 and 774. The identification of these alterations is key for an adequate management of NSCLC patients due to the possibility to treat these patients with specific targeted therapies. Next generation sequencing (NGS) technology, able to detect several hotspot gene mutations for different patients simultaneously, is the best detection approach due to its higher sensitivity and specificity compared to other techniques. Here we reviewed the principal biological characteristics, the main detection technologies and treatment options for NSCLC patients harbouring EGFR exon 20 insertions.
Identifiants
pubmed: 34801697
pii: S1040-8428(21)00323-1
doi: 10.1016/j.critrevonc.2021.103536
pii:
doi:
Substances chimiques
Protein Kinase Inhibitors
0
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103536Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.